EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Henry Schein, Inc. (H1SI34) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Henry Schein, Inc. BRL 125, price BRL 233, upside -46.5%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · Home US

HS Some data Oct 3, 2026

Henry Schein, Inc.

H1SI34 · SA

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value R$124.86 · Strongly overvalued (−46.5%)
✓Quality 60/100
!Weak Growth (revenue 3y +1.4 %/yr)
!Thin margins · 3.0% net margin (TTM)
✓Moderate debt · generates free cash flow
!Mixed vs. peers (6/13)
!Narrow moat 39/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 21 out of 100
Watch Henry Schein, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$234.78 R$180.72 Fair Value R$124.86 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range R$180.72 – R$234.78 · fair‑value band R$71.60 – R$188.02 · the R$233.22 price screens above the R$124.86 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Henry Schein in your weekly email

Every Wednesday you see whether Henry Schein is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.

Show more

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Stock analysis

Henry Schein, Inc. (H1SI34) currently trades at R$233.22, while our model-based Fair Value estimate is R$124.86, 46.5% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of R$155.09 per share, and 0 of the 22 models we run sit above the R$233.22 price.

Bear case: the Asset-Based group reads lowest at R$49.83, and 22 of the 22 models stay below the price. Evidence for this calculation is medium.

Scenario range: R$71.60 (bear) to R$188.02 (bull), the price of R$233.22 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Henry Schein, Inc. reported revenue of $13.2B in FY2025 versus $12.4B in FY2021, a compound +1.5%/yr. Reported net income was $398M in FY2025, compounding −10.9%/yr from FY2021.

Key figures

Market cap R$43.5B (≈ $8.3B) · P/E ratio 27.9 · P/S ratio 0.84 · EPS (TTM) R$8.37 · Net margin 3.0% · Return on equity 8.8% · Return on assets (EBIT) 7.3% · Operating margin 5.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at −46%, H1SI34 screens richer than that median.

Fair Value models

Bear R$71.60 Fair Value R$124.86 Bull R$188.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$6.33 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$93.86 R$144.61 R$225.14 76
Growth DCF R$98.51 R$146.94 R$219.20 75
Owner Earnings R$93.19 R$143.70 R$223.85 72
All 22 models by family
DCF Models
FCF DCF R$93.86 R$144.61 R$225.14 76
Owner Earnings R$93.19 R$143.70 R$223.85 72
5Y Revenue Exit R$83.57 R$143.51 R$223.52 68
5Y EBITDA Exit R$111.76 R$192.10 R$289.48 71
5Y P/E Exit R$86.02 R$147.73 R$214.65 67
10Y Revenue Exit R$82.79 R$135.33 R$196.50 63
10Y EBITDA Exit R$103.42 R$166.93 R$240.69 65
10Y P/E Exit R$87.87 R$138.07 R$190.56 61
Earnings-Based
Graham-Dodd R$62.03 R$117.21 R$145.83 63
EPV R$58.12 R$75.10 R$89.74 71
Multiples
P/E Multiple R$150.53 R$200.70 R$250.88 63
P/S Multiple R$116.32 R$155.09 R$193.86 58
P/B Multiple R$116.32 R$155.09 R$193.86 55
EV/EBIT R$152.69 R$220.05 R$287.40 65
EV/EBITDA R$149.49 R$215.78 R$282.07 67
EV/Revenue R$86.83 R$145.21 R$203.58 52
Asset-Based
NCAV (Graham) R$37.19 R$49.83 R$74.38 54
Growth DCF
Growth DCF R$98.51 R$146.94 R$219.20 75
Rev-Margin DCF R$83.57 R$145.90 R$217.62 69
Economic Profit
Residual Income R$68.81 R$78.92 R$99.48 68
ROIC Compounder R$58.12 R$75.25 R$95.02 69
Growth Earnings
Growth-Adj P/E R$107.35 R$153.36 R$199.37 65

Open the full fair value analysis →

Notify me when H1SI34 reaches fair value

Put H1SI34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 60/100

Of which business quality 59 · Market factors (momentum, volatility) 70

Profitability 53
Margins and returns on capital today
Quality Growth 35
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 82
Calm price path (market factor)
Momentum 59
Price trend over the last 3–12 months (market factor)
52W Momentum 77
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 5%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +7.8% a year for the price and +1.2% for the forecasts.
Forecast 2026 (sales)+4.3%
Forecast 2027 (sales)+3.7%
Projected 2028 (sales)+3.5%
Projected 2029 (sales)+3.3%
Projected 2030 (sales)+3.1%

H1SI34 screens overvalued: fair value 46% below the price. Compare with McKesson Corporation →

Compare Henry Schein, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 60 · Top 25%
Fair Value upside −9.6% · Below median
Profitability
Return on equity (TTM) 8.8% · Above median
Return on assets 4.4% · Top 25%
Net margin (TTM) 3.0% · Above median
Operating margin (TTM) 5.9% · Top 25%
Growth and dividend
Revenue growth 6.3% · Above median
Balance sheet
Debt / equity 0.71× · Highest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 27.9× · Priciest 25%
P/B 2.57× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 0.62× · Pricier than median
P/FCF 16.0× · Pricier than median
EV/EBITDA 10.0× · Pricier than median
PEG 1.62× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 45
FUTURE (revenue growth)32 · sector 13
PAST (return on equity)35 · sector 28
HEALTH (low debt)64 · sector 97
DIVIDEND (yield)0 · sector 58

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $864.82 $822.74 −5%
Cencora, Inc COR $309.78 $215.20 −31%
Cardinal Health, Inc CAH $220.29 $162.84 −26%
Shanghai Pharmaceuticals Holding 601607 ¥16.02 ¥42.67 +166%
Sinopharm Group 1099 HK$14.88 HK$55.77 +275%
Galenica AG GALE CHF 82.55 CHF 61.79 −25%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.39 ¥26.64 +37%
Jointown Pharmaceutical Group 600998 ¥5.05 ¥9.84 +95%
China National Medicines Corporation 600511 ¥25.80 ¥58.47 +127%
Hanmi Science Co 008930 52,800 KRW 21,059 KRW −60%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Henry Schein, Inc. · Fair Value
R$124.86 −46%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Henry Schein, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/H1SI34

Frequently asked questions

Is Henry Schein, Inc. (H1SI34) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of R$124.86 versus a price of R$233.22, about −46% upside (overvalued).
What is the fair value of H1SI34?
Our model-based fair value for Henry Schein, Inc. is R$124.86 (as of Oct 3, 2026), built from audited fundamentals. The current price: R$233.22.
What is the quality score of H1SI34?
Henry Schein, Inc. has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Henry Schein, Inc. (H1SI34)?
Our model-based price target is the fair value of R$124.86 (as of Oct 3, 2026) from 22 valuation models. Cautious scenario R$71.60, optimistic scenario R$188.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Henry Schein, Inc. stock forecast for 2026?
Our models put fair value at R$124.86, about −46% upside versus a price of R$233.22 (overvalued). Cautious scenario R$71.60, optimistic scenario R$188.02. The calculation is refreshed regularly with new filings.
What is the revenue of Henry Schein, Inc. (H1SI34)?
Henry Schein, Inc. reported trailing-twelve-month revenue of about $13.4B (latest available figure, as of Oct 3, 2026).
What growth is priced into Henry Schein, Inc. (H1SI34)?
For today's price to be fair in a discounted-cash-flow model, Henry Schein, Inc. would have to grow free cash flow by +10.4 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +1.5 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of H1SI34 use?
Our models discount Henry Schein, Inc. at 12.1 %: a base by market capitalisation (mid), damped by beta 0.81, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Henry Schein, Inc. that is +10.4 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Henry Schein, Inc. (H1SI34) delivered so far?
Over the past 4 years revenue at Henry Schein, Inc. grew +1.5 % a year. The price currently implies +10.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Henry Schein, Inc. (H1SI34) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Henry Schein, Inc. (+10.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Henry Schein, Inc. (H1SI34)?
The free-cash-flow yield on the price is 10.08 %: that much free cash flow Henry Schein, Inc. produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Henry Schein, Inc. (H1SI34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Henry Schein, Inc. it is R$124.86 per share (as of Oct 3, 2026), against a price of R$233.22. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Henry Schein, Inc. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, H1SI34 trades above its calculated fair value: price R$233.22, fair value R$124.86, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of H1SI34?
No. The price is what the market pays today (R$233.22); the fair value is what the company's own numbers justify (R$124.86). For Henry Schein, Inc. the two are R$108.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Henry Schein, Inc. worth?
The market values Henry Schein, Inc. at about R$43.5B (market capitalisation, as of Oct 3, 2026). Per share that is R$233.22; our models calculate a fair value of R$124.86 per share.
What do the bullish and bearish scenarios say about H1SI34?
Our models span a range for Henry Schein, Inc.: cautious scenario R$71.60, base R$124.86, optimistic R$188.02 per share (as of Oct 3, 2026, price R$233.22). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of H1SI34?
Henry Schein, Inc. trades at a price-to-earnings ratio of 27.9 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$124.86 is built from several models across several years. Other multiples: PEG 1.6, P/B 2.6, P/S 0.6, EV/EBITDA 10.0.
What is the PEG ratio of H1SI34?
The PEG ratio of Henry Schein, Inc. is 1.62 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Henry Schein, Inc. (H1SI34)?
Balance-sheet figures for Henry Schein, Inc. (as of Oct 3, 2026): return on equity 8.8%, debt of 0.71 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is H1SI34 from its 52-week high?
Henry Schein, Inc. trades at R$233.22, about 1% below its 52-week high of R$234.78 and 22% above the low of R$190.76 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$124.86 is for.
Which stocks are comparable to Henry Schein, Inc.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Shanghai Pharmaceuticals Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Henry Schein, Inc. stock attractive at the current price?
The data as of Oct 3, 2026: price R$233.22, calculated fair value R$124.86 (−46%), Quality Score 60/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of H1SI34 calculated?
We run Henry Schein, Inc. through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$124.86, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Henry Schein, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Henry Schein, Inc. (H1SI34)?
The closing price on Oct 1, 2026 was R$233.22. Our model-based fair value is R$124.86, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Henry Schein, Inc. right now?
The price sits above even our optimistic bull case (R$188.02). The favourable scenario is already priced in. The model range is unusually wide (R$71.60 to R$188.02). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Henry Schein, Inc.

How large is the market capitalisation of Henry Schein, Inc. (H1SI34)?
The market capitalisation of Henry Schein, Inc. is R$43.5B (≈ $8.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Henry Schein, Inc. (H1SI34)?
The price-to-sales ratio of Henry Schein, Inc. is 0.84 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Henry Schein, Inc. (H1SI34)?
Earnings per share at Henry Schein, Inc. are R$8.37 (price ÷ EPS = P/E 27.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Henry Schein, Inc. (H1SI34)?
The net margin of Henry Schein, Inc. is 3.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Henry Schein, Inc. (H1SI34)?
The return on equity (ROE) of Henry Schein, Inc. is 8.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Henry Schein, Inc. (H1SI34)?
On an EBIT basis the return on assets of Henry Schein, Inc. is 7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Henry Schein, Inc. (H1SI34)?
The operating margin of Henry Schein, Inc. is 5.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Henry Schein, Inc. (H1SI34)?
Revenue at Henry Schein, Inc. is growing +6.3% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Henry Schein, Inc. (H1SI34)?
Earnings per share at Henry Schein, Inc. are growing +4.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Henry Schein, Inc. (H1SI34) carry?
The net debt of Henry Schein, Inc. is $3.0B (fiscal year 2025, ≈ 5.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Henry Schein, Inc. in the live analysis

One click puts Henry Schein, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.